NELARABINE-REACH (Reach Pharmaceuticals Pty Ltd)
Nelarabine is indicated for the treatment of patients with relapsing /refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment.
Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.